Up next

DCAT Week ’17 Member Company Announcement Forum: Tracking the Pharma Manufacturing Value Chain

Senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions, at the DCAT Member Company Announcement Forum at DCAT Week ’17. DCAT Value Chain Insights highlights the latest developments.

Developments in Drug-Substance Manufacturing
Noramco CEO Discusses Strategy as Stand-Alone Company

Patheon Integrates Former Roche API Manufacturing Facility

BioVectra Outlines API Manufacturing Expansion

Novasep Opens New Bioconjugation Facility for ADCs

Olon Highlights Integration of Infa

CMC Biologics Updates Acquisition by AGC Asahi Glass

Developments in Drug-Product Development and Manufacturing
Mayne Pharma Specifies Timeline for $80-Million Expansion

Catalent Integrates Pharmatek and Accucaps Acquisitions

Lubrizol’s Particle Sciences Expands Manufacturing

Developments in both Drug Substance and Drug Product Manufacturing:
Siegfried CEO Outlines Five-Year Strategic Plan

CordenPharma Expands Oligonucletides and Sterile Injectables

Developments in Packaging
Datwyler Outlines $100-Million Manufacturing Expansion

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

2025: The Bio/Pharma Industry’s Year in Review

By
Without question, US-imposed tariffs and ensuing trade deals and the impact on the bio/pharma industry was the number one news story in 2025, going hand-in-hand with US manufacturing investments and drug pricing reforms. What else made the news?

UK, US Strike Agreement for Drug Pricing & Tariffs

By
The UK and the US governments have agreed in principle on drug pricing and tariffs/trade on pharmaceuticals between the two countries, months after the countries formed an initial trade pact. What is the new deal and the impact on pharma?

Raising the Bar: The Innovation Leaders

By
Innovation is central to the bio/pharma industry, so what have been the key developments in 2025? Which companies and their innovation stand out? DCAT Value Chain Insights takes an inside look.

Global Impact: US Tariffs, Pharma & GDP

By
What has been the impact of US tariffs thus far on global trade, including on pharmaceuticals and pharmaceutical ingredients? Plus, Switzerland is the latest country to strike a new tariff deal.